Table 2. The patients' characteristics before and after PSM.
| Characteristics | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| Euglycemia (n = 341) | Hyperglycemia (n = 82) | p-value* | Euglycemia (n = 75) | Hyperglycemia (n = 75) | p-value* | ||
| Age (yr) | 0.002 | 0.743 | |||||
| < 50 | 240 (70.4) | 42 (51.2) | 43 (57.3) | 40 (53.3) | |||
| ≥ 50 | 101 (29.6) | 40 (48.8) | 32 (42.7) | 35 (46.7) | |||
| Hypertension | 0.039 | 0.158 | |||||
| Yes | 31 (9.1) | 15 (18.3) | 7 (9.3) | 14 (18.7) | |||
| No | 310 (90.9) | 67 (81.7) | 68 (90.7) | 61 (81.3) | |||
| Hyperlipidemia | 0.178 | 0.586 | |||||
| Yes | 27 (7.9) | 11 (13.4) | 6 (8.0) | 9 (12.0) | |||
| No | 314 (92.1) | 71 (86.6) | 69 (92.0) | 66 (88.0) | |||
| BMI (kg/m2) | 0.001 | 0.052 | |||||
| < 23 | 140 (41.1) | 17 (20.7) | 29 (38.7) | 17 (22.7) | |||
| ≥ 23 | 201 (58.9) | 65 (79.3) | 46 (61.3) | 58 (77.3) | |||
| Tumor location | 0.587 | 0.189 | |||||
| Right | 172 (50.4) | 38 (46.3) | 46 (61.3) | 37 (49.3) | |||
| Left | 169 (49.6) | 44 (53.7) | 29 (38.7) | 38 (50.7) | |||
| BCS | 0.150 | 0.481 | |||||
| Yes | 254 (74.5) | 54 (65.9) | 54 (72.0) | 49 (65.3) | |||
| No | 87 (25.5) | 28 (34.1) | 21 (28.0) | 26 (34.7) | |||
| SLNB | 0.012 | 1.000 | |||||
| Yes | 184 (54.0) | 31 (37.8) | 31 (41.3) | 30 (40.0) | |||
| No | 157 (46.0) | 51 (62.2) | 44 (58.7) | 45 (60.0) | |||
| Pathologic subtype | 0.546 | 0.562 | |||||
| IDC | 317 (93.0) | 74 (90.2) | 70 (93.3) | 67 (89.3) | |||
| Others | 24 (7.0) | 8 (9.8) | 5 (6.7) | 8 (10.7) | |||
| T stage | 0.275 | 1.000 | |||||
| T1 | 171 (50.1) | 35 (42.7) | 33 (44.0) | 32 (42.7) | |||
| ≤ T2 | 170 (49.9) | 47 (57.3) | 42 (56.0) | 43 (57.3) | |||
| N stage | 0.025 | 0.291 | |||||
| N0 | 166 (48.7) | 28 (34.1) | 20 (26.7) | 27 (36.0) | |||
| ≤ N1 | 175 (51.3) | 54 (65.9) | 55 (73.3) | 48 (64.0) | |||
| Estrogen receptor | 0.923 | 1.000 | |||||
| Positive | 258 (75.7) | 61 (74.4) | 53 (70.7) | 54 (72.0) | |||
| Negative | 83 (24.3) | 21 (25.6) | 22 (29.3) | 21 (28.0) | |||
| Progesterone receptor | 0.654 | 0.600 | |||||
| Positive | 244 (71.6) | 56 (68.3) | 53 (70.7) | 49 (65.3) | |||
| Negative | 97 (28.4) | 26 (31.7) | 22 (29.3) | 26 (34.7) | |||
| HER-2 | 1.000 | 0.866 | |||||
| Positive | 123 (36.1) | 29 (35.4) | 29 (38.7) | 27 (36.0) | |||
| Negative | 218 (63.9) | 53 (64.6) | 46 (61.3) | 48 (64.0) | |||
| Vascular invasion | 0.786 | 1.000 | |||||
| Present | 13 (3.8) | 2 (2.4) | 1 (1.3) | 2 (2.7) | |||
| Absent | 328 (96.2) | 80 (97.6) | 74 (98.7) | 73 (97.3) | |||
| Lymphatic invasion | 0.308 | 0.810 | |||||
| Present | 34 (10.0) | 12 (14.6) | 9 (12.0) | 11 (14.7) | |||
| Absent | 307 (90.0) | 70 (85.4) | 66 (88.0) | 64 (85.3) | |||
| p53 | 1.000 | 1.000 | |||||
| Positive | 143 (41.9) | 35 (42.7) | 32 (42.7) | 32 (42.7) | |||
| Negative | 198 (58.1) | 47 (57.3) | 43 (57.3) | 43 (57.3) | |||
| Ki67 (%) | 0.602 | 0.305 | |||||
| < 14 | 120 (35.2) | 32 (39.0) | 23 (30.7) | 30 (40.0) | |||
| ≥ 14 | 221 (64.8) | 50 (61.0) | 52 (69.3) | 45 (60.0) | |||
| Radiotherapy | 0.312 | 0.829 | |||||
| Yes | 296 (86.8) | 67 (81.7) | 63 (84.0) | 61 (81.3) | |||
| No | 45 (13.2) | 15 (18.3) | 12 (16.0) | 14 (18.7) | |||
| Hormone therapy | 1.000 | 0.705 | |||||
| Yes | 260 (76.2) | 62 (75.6) | 58 (77.3) | 55 (73.3) | |||
| No | 81 (23.8) | 20 (24.4) | 17 (22.7) | 20 (26.7) | |||
| Target therapy | 1.000 | 0.865 | |||||
| Yes | 118 (34.6) | 28 (34.1) | 28 (37.3) | 26 (34.7) | |||
| No | 223 (65.4) | 54 (65.9) | 47 (62.7) | 49 (65.3) | |||
| Total steroid dosage (mg) | < 0.001 | 1.000 | |||||
| < 50 | 164 (48.1) | 13 (15.9) | 13 (17.3) | 13 (17.3) | |||
| 50–149 | 156 (45.7) | 48 (58.5) | 46 (61.3) | 46 (61.3) | |||
| 150–249 | 21 (6.2) | 21 (25.6) | 16 (21.3) | 16 (21.3) | |||
PSM = propensity score matching; BMI = body mass index; BCS = breast conserving surgery; SLNB = sentinel lymph node biopsy; IDC = invasive ductal carcinoma; HER-2 = human epidermal growth factor receptor 2.
*Pearson's χ2 test.